Mayur Ian Somaiya, Chief Financial Officer at NewAmsterdam Pharma Co N.V. (NAMS), sold 100,000 shares at $30.64 ($3.3M) on 2026-01-20, disclosed to the SEC on 2026-01-22.
Open-market sale of $3.3M NAMS by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.64 | 900 | $28K | 0.8% |
| 2 | $31.78 | 39,712 | $1.3M | 38.7% |
| 3 | $32.38 | 19,604 | $635K | 19.5% |
| 4 | $33.25 | 15,422 | $513K | 15.7% |
| 5 | $33.80 | 24,362 | $823K | 25.3% |
| Total | $32.61 avg | 100,000 |
| $3.3M |
| 100% |
| Filing → |
| TCRR | SELL | 2020-11-19 | $110K | — | Filing → |